Sigyn Therapeutics Appoints Dr. Christoph Zaba to Scientific Advisory Board to Advance Cardiovascular Treatment Technology

Sigyn Therapeutics, Inc. has appointed Dr. Christoph Zaba to its Scientific Advisory Board, bringing extensive experience in medical technology and extracorporeal therapies to advance the company's dialysis-like treatments for cardiovascular disease and cancer. Dr. Zaba previously directed global product management in therapeutic apheresis at Fresenius Medical Care, focusing on immunoadsorption therapies for autoimmune diseases and lipoprotein apheresis for removing pathogenic lipoproteins from blood.

Lipoprotein apheresis (LA) is an established extracorporeal treatment that reduces lipoprotein(a) [Lp(a)] and low-density lipoprotein cholesterol [LDL-C] in the bloodstream, with studies reporting 55% to 98% reductions in major adverse cardiovascular events (MACE). However, treatment access is limited to fewer than 60 specialized apheresis centers in the United States. In contrast, Sigyn Therapy™ is designed for use on dialysis machines already located in approximately 7,500 U.S. dialysis clinics, potentially expanding accessibility significantly.

Sigyn Therapy™ is a whole blood adsorption technology aimed at reducing Lp(a) and LDL-C while targeting inflammatory molecules that fuel cardiovascular disease progression. The company recently disclosed plans to commence a multi-site clinical feasibility study in high-risk cardiovascular disease subjects with end-stage renal disease. Successful completion could lead to a pivotal efficacy study necessary for potential market clearance. Cardiovascular disease remains the leading cause of global deaths, underscoring the importance of innovative treatments like Sigyn Therapy™.

Beyond cardiovascular applications, Sigyn Therapeutics is developing dialysis-like cancer therapies, including ImmunePrep™ to optimize immunotherapeutic antibody delivery, ChemoPrep™ to enhance targeted chemotherapy delivery, and ChemoPure™ to reduce chemotherapy toxicity. These candidates are planned for advancement through joint venture development relationships. For more information, visit https://www.sigyntherapeutics.com.